Oragenics, Inc. Logo

Oragenics, Inc.

OGEN

(1.5)
Stock Price

0,48 USD

-102.5% ROA

-87.51% ROE

-1.73x PER

Market Cap.

15.314.592,00 USD

7.97% DER

0% Yield

-4785.95% NPM

Oragenics, Inc. Stock Analysis

Oragenics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Oragenics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (4%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.01x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

4 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

5 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

6 ROE

Negative ROE (-90.91%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

7 ROA

The stock's ROA (-117.73%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Oragenics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Oragenics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Oragenics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Oragenics, Inc. Revenue
Year Revenue Growth
2003 0
2004 196.210 100%
2005 0 0%
2006 66.176 100%
2007 133.088 50.28%
2008 233.539 43.01%
2009 641.285 63.58%
2010 1.308.910 51.01%
2011 1.444.447 9.38%
2012 1.331.764 -8.46%
2013 1.032.233 -29.02%
2014 939.926 -9.82%
2015 1.175.841 20.06%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 86.987 100%
2022 131.521 33.86%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Oragenics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2003 929.355
2004 1.990.979 53.32%
2005 2.097.223 5.07%
2006 2.023.896 -3.62%
2007 1.569.551 -28.95%
2008 1.955.488 19.74%
2009 1.833.746 -6.64%
2010 2.014.784 8.99%
2011 2.449.178 17.74%
2012 7.860.987 68.84%
2013 9.358.957 16.01%
2014 3.065.053 -205.34%
2015 8.803.033 65.18%
2016 4.754.650 -85.15%
2017 3.539.656 -34.33%
2018 5.971.833 40.73%
2019 12.120.318 50.73%
2020 22.107.563 45.18%
2021 10.586.144 -108.83%
2022 10.072.684 -5.1%
2023 3.077.400 -227.31%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Oragenics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 738.596
2004 1.329.983 44.47%
2005 1.166.854 -13.98%
2006 1.004.099 -16.21%
2007 902.655 -11.24%
2008 4.312.246 79.07%
2009 4.917.844 12.31%
2010 6.285.004 21.75%
2011 5.628.005 -11.67%
2012 5.024.616 -12.01%
2013 7.540.152 33.36%
2014 3.321.771 -126.99%
2015 3.543.184 6.25%
2016 3.787.855 6.46%
2017 3.178.662 -19.17%
2018 4.022.307 20.97%
2019 3.757.251 -7.05%
2020 4.533.893 17.13%
2021 5.271.861 14%
2022 4.474.465 -17.82%
2023 5.330.248 16.06%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Oragenics, Inc. EBITDA
Year EBITDA Growth
2003 -1.655.406
2004 -3.082.765 46.3%
2005 -3.003.441 -2.64%
2006 -2.682.942 -11.95%
2007 -2.063.979 -29.99%
2008 -5.762.691 64.18%
2009 -6.090.821 5.39%
2010 -7.856.279 22.47%
2011 -7.265.803 -8.13%
2012 -12.341.946 41.13%
2013 -16.110.197 23.39%
2014 -5.751.830 -180.09%
2015 -11.559.589 50.24%
2016 -8.427.371 -37.17%
2017 -6.642.294 -26.87%
2018 -9.878.245 32.76%
2019 -15.496.081 36.25%
2020 -26.501.062 41.53%
2021 -15.654.621 -69.29%
2022 -14.228.619 -10.02%
2023 -7.975.720 -78.4%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Oragenics, Inc. Gross Profit
Year Gross Profit Growth
2003 0
2004 196.210 100%
2005 0 0%
2006 66.176 100%
2007 133.088 50.28%
2008 218.675 39.14%
2009 420.087 47.95%
2010 397.117 -5.78%
2011 730.820 45.66%
2012 453.303 -61.22%
2013 688.879 34.2%
2014 570.329 -20.79%
2015 694.098 17.83%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 86.987 100%
2022 131.521 33.86%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Oragenics, Inc. Net Profit
Year Net Profit Growth
2003 -1.672.954
2004 -3.077.888 45.65%
2005 -3.251.378 5.34%
2006 -2.935.719 -10.75%
2007 -2.311.712 -26.99%
2008 -6.021.742 61.61%
2009 -5.519.348 -9.1%
2010 -7.805.165 29.29%
2011 -7.678.868 -1.64%
2012 -13.090.446 41.34%
2013 -16.068.754 18.53%
2014 -5.789.519 -177.55%
2015 -11.711.333 50.56%
2016 -7.013.304 -66.99%
2017 -6.731.525 -4.19%
2018 -9.914.141 32.1%
2019 -15.573.759 36.34%
2020 -26.443.179 41.1%
2021 -15.728.040 -68.13%
2022 -14.161.150 -11.06%
2023 -8.051.540 -75.88%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Oragenics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 -1.510
2004 -2.635 42.73%
2005 -2.589 -1.82%
2006 -1.759 -47.21%
2007 -1.106 -59.1%
2008 -2.061 46.36%
2009 -1.021 -101.96%
2010 -850 -20.14%
2011 -806 -5.47%
2012 -443 -82.13%
2013 -335 -31.94%
2014 -96 -248.96%
2015 -192 49.74%
2016 -94 -103.19%
2017 -82 -16.05%
2018 -46 -80%
2019 -22 -104.55%
2020 -28 21.43%
2021 -8 -250%
2022 -7 -14.29%
2023 -3 -133.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Oragenics, Inc. Free Cashflow
Year Free Cashflow Growth
2003 -1.269.168
2004 -3.435.791 63.06%
2005 -4.100.650 16.21%
2006 -2.236.549 -83.35%
2007 -1.926.666 -16.08%
2008 -3.890.512 50.48%
2009 -5.808.554 33.02%
2010 -6.536.518 11.14%
2011 -5.494.758 -18.96%
2012 -5.222.952 -5.2%
2013 -6.783.342 23%
2014 -5.669.803 -19.64%
2015 -5.206.896 -8.89%
2016 -7.102.264 26.69%
2017 -6.363.853 -11.6%
2018 -9.204.544 30.86%
2019 -13.038.057 29.4%
2020 -16.952.864 23.09%
2021 -13.514.088 -25.45%
2022 -15.356.002 11.99%
2023 -1.503.012 -921.68%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Oragenics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2003 -1.218.910
2004 -2.745.243 55.6%
2005 -3.434.382 20.07%
2006 -2.224.538 -54.39%
2007 -1.913.760 -16.24%
2008 -3.835.190 50.1%
2009 -5.799.481 33.87%
2010 -6.448.434 10.06%
2011 -5.494.758 -17.36%
2012 -5.211.857 -5.43%
2013 -6.764.533 22.95%
2014 -5.559.130 -21.68%
2015 -5.104.385 -8.91%
2016 -7.075.085 27.85%
2017 -6.363.853 -11.18%
2018 -9.079.817 29.91%
2019 -13.012.843 30.22%
2020 -16.952.864 23.24%
2021 -13.470.212 -25.85%
2022 -15.228.483 11.55%
2023 -1.503.012 -913.2%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Oragenics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2003 50.258
2004 690.548 92.72%
2005 666.268 -3.64%
2006 12.011 -5447.15%
2007 12.906 6.93%
2008 55.322 76.67%
2009 9.073 -509.74%
2010 88.084 89.7%
2011 0 0%
2012 11.095 100%
2013 18.809 41.01%
2014 110.673 83%
2015 102.511 -7.96%
2016 27.179 -277.17%
2017 0 0%
2018 124.727 100%
2019 25.214 -394.67%
2020 0 0%
2021 43.876 100%
2022 127.519 65.59%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Oragenics, Inc. Equity
Year Equity Growth
2003 3.439.897
2004 4.036.444 14.78%
2005 1.771.570 -127.85%
2006 1.278.274 -38.59%
2007 819.883 -55.91%
2008 -177.248 562.56%
2009 2.639.627 106.71%
2010 -1.899.316 238.98%
2011 -8.179.318 76.78%
2012 9.231.646 188.6%
2013 15.838.635 41.71%
2014 10.336.148 -53.24%
2015 4.731.025 -118.48%
2016 2.965.723 -59.52%
2017 6.316.309 53.05%
2018 20.881.983 69.75%
2019 17.231.652 -21.18%
2020 16.844.595 -2.3%
2021 26.486.199 36.4%
2022 13.009.302 -103.59%
2023 6.497.321 -100.23%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Oragenics, Inc. Assets
Year Assets Growth
2003 3.650.765
2004 4.466.071 18.26%
2005 2.146.400 -108.07%
2006 1.605.847 -33.66%
2007 1.151.377 -39.47%
2008 1.594.123 27.77%
2009 3.202.836 50.23%
2010 1.727.663 -85.39%
2011 1.266.952 -36.36%
2012 10.488.132 87.92%
2013 16.831.482 37.69%
2014 11.132.420 -51.19%
2015 5.778.379 -92.66%
2016 4.309.166 -34.1%
2017 7.214.831 40.27%
2018 22.049.552 67.28%
2019 19.752.717 -11.63%
2020 18.680.532 -5.74%
2021 28.230.979 33.83%
2022 14.758.025 -91.29%
2023 7.899.428 -86.82%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Oragenics, Inc. Liabilities
Year Liabilities Growth
2003 210.868
2004 429.627 50.92%
2005 374.830 -14.62%
2006 327.573 -14.43%
2007 331.494 1.18%
2008 1.771.371 81.29%
2009 563.209 -214.51%
2010 3.626.979 84.47%
2011 9.446.270 61.6%
2012 1.256.486 -651.8%
2013 992.847 -26.55%
2014 796.272 -24.69%
2015 1.047.354 23.97%
2016 1.343.443 22.04%
2017 898.522 -49.52%
2018 1.167.569 23.04%
2019 2.521.065 53.69%
2020 1.835.937 -37.32%
2021 1.744.780 -5.22%
2022 1.748.723 0.23%
2023 1.402.107 -24.72%

Oragenics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.06
Net Income per Share
-3.44
Price to Earning Ratio
-1.73x
Price To Sales Ratio
116.44x
POCF Ratio
-1.63
PFCF Ratio
-1.78
Price to Book Ratio
2.16
EV to Sales
76.53
EV Over EBITDA
-1.24
EV to Operating CashFlow
-1.17
EV to FreeCashFlow
-1.17
Earnings Yield
-0.58
FreeCashFlow Yield
-0.56
Market Cap
0,02 Bil.
Enterprise Value
0,01 Bil.
Graham Number
14.6
Graham NetNet
1.86

Income Statement Metrics

Net Income per Share
-3.44
Income Quality
1.05
ROE
-0.88
Return On Assets
-1.02
Return On Capital Employed
-1.3
Net Income per EBT
0.99
EBT Per Ebit
0.97
Ebit per Revenue
-50.06
Effective Tax Rate
0.01

Margins

Sales, General, & Administrative to Revenue
34.83
Research & Developement to Revenue
29.85
Stock Based Compensation to Revenue
3.43
Gross Profit Margin
0.76
Operating Profit Margin
-50.06
Pretax Profit Margin
-48.54
Net Profit Margin
-47.86

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.66
Free CashFlow per Share
-3.66
Capex to Operating CashFlow
0
Capex to Revenue
-0.03
Capex to Depreciation
-0.08
Return on Invested Capital
-1.2
Return on Tangible Assets
-1.02
Days Sales Outstanding
97.42
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
3.75
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
2,45
Book Value per Share
2,76
Tangible Book Value per Share
2.76
Shareholders Equity per Share
2.76
Interest Debt per Share
0.23
Debt to Equity
0.08
Debt to Assets
0.07
Net Debt to EBITDA
0.64
Current Ratio
5.57
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0.08
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Oragenics, Inc. Dividends
Year Dividends Growth

Oragenics, Inc. Profile

About Oragenics, Inc.

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

CEO
Mr. Charles L. Pope CPA
Employee
6
Address
4902 Eisenhower Boulevard
Tampa, 33634

Oragenics, Inc. Executives & BODs

Oragenics, Inc. Executives & BODs
# Name Age
1 Mr. Charles L. Pope CPA
Executive Chairman
70
2 Ms. Janet Huffman
Chief Financial Officer, Secretary & Treasurer
70
3 Mr. Joseph Michael Redmond
President & Interim Principal Executive Officer
70

Oragenics, Inc. Competitors